CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for IASO Pharma Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

IASO Pharma Inc
12707 High Bluff Dr Ste 200
Phone: (858) 350-4312p:858 350-4312 SAN DIEGO, CA  92130-2037  United States Fax: (800) 253-5177f:800 253-5177

Business Summary
IASO Pharma Inc., formerly Pacific Beach BioSciences, Inc., is a biopharmaceutical company that seeks to in-license, develop and commercialize therapeutic products for the treatment and prevention of infectious diseases. The Company has obtained rights to candidates for the treatment of bacterial and fungal infections. During the year ended December 31, 2009, the Company licensed all of the products in its pipeline. Its product candidates focus to address market opportunities in the antibiotic and antifungal markets, including its advanced product candidate, PB-101 (zabofloxacin). PB-101 is a fluoroquinolone antibiotic, it plans to develop for the treatment of community-acquired pneumonia (CAP). In the antifungal market, it is focused on developing PB-200a, a drug candidate, and PB-201, a technology that may result in one or more additional drug candidates.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
3/31/201112/31/2010YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, Chief & Principal Executive Officer, Director Matthew A.Wikler 70 2/28/2010 11/1/2006
Chief & Principal Financial Officer, Executive Vice President, Chief Accounting Officer James W.Klingler 63 7/12/2010 7/12/2010
Vice President - Regulatory Affairs Mark W.Lotz 59 5/1/2007 5/1/2007
6 additional Officers and Directors records available in full report.

Business Names
Business Name
IASO
IASO PHARMA INC

General Information
Number of Employees: 4 (As of 6/24/2011)
Outstanding Shares: 950,001 (As of 3/31/2011)
Stock Exchange: AMEX
Federal Tax Id: 205686081
Fax Number: (800) 253-5177


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023